Latest Glycated hemoglobin Stories
Intensive treatment provides no benefit over standard when it comes to memory Intensive control of blood sugar levels beyond standard targets provides no additional protection against cognitive decline in older people with diabetes than standard treatment, according to a national study coordinated by researchers at Wake Forest Baptist Medical Center. The first results of the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) study appear online today in...
Doctor-patient encounters associated with lower blood glucose, cholesterol and blood pressure levels in patients with diabetes The risk for diabetes complications, such as heart attack and stroke, increases with high blood glucose, blood pressure and cholesterol levels. Reducing risk means reducing these values to ideal levels. According to researchers at Brigham and Women's Hospital (BWH), achieving ideal levels may be as simple as seeing your doctor. They found that frequent...
Visiting a primary care clinician every two weeks was associated with greater control of blood glucose, blood pressure and cholesterol levels among patients with diabetes, according to a report in the September 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Diabetes has become increasingly common in the United States and the world, according to background information in the article. Elevated levels of hemoglobin A1c (a measure of blood glucose levels and...
A recent Phase III investigation by has demonstrated that a new medication for the treatment of Type 2 diabetes significantly lowers blood glucose levels in adults while exhibiting few side effects and maintaining positive results over the duration of the study as reported by DiabeticLive.com. Tampa, FL (PRWEB) September 21, 2011 New Type 2 Diabetes Medication Reduces Blood Glucose Safely: A recent Phase III investigation has demonstrated that a new medication for the treatment of Type 2...
WORCESTER, Mass. and TORONTO, Sept. 16, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that Dr. Nicola Napolii, from University Campus Bio-Medico in Rome, Italy, made a podium presentation of the clinical data on Generex Oral-lyn(TM) buccal insulin spray on September 14, 2011 at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b...
MOUNTAIN VIEW, Calif., Sept. 15, 2011 /PRNewswire/ -- ChemoCentryx, Inc. today announced that the Company's novel, orally active CCR2 antagonist, CCX140-B, demonstrated an excellent safety profile and exhibited clear signs of biological and clinical effect in a Phase II study in patients with type 2 diabetes on stable doses of metformin. While demonstrating safety and tolerability, a statistically significant decrease in hemoglobin A1c (HbA1c) relative to placebo and a dose-dependent...
HAYWARD, Calif., Sept. 14, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today the presentation of final 48-week results from a phase 2 clinical study of ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) for the treatment of type 2 diabetes at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal. (Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO) Results of the phase 2 study, presented by Julio...
PARIS, Sept. 12, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin. The study objectives were to compare the efficacy and safety of lixisenatide versus placebo in one-step and two-step dose increase regimens in terms of reduction in HbA1c....
MODESTO, Calif., Sept. 7, 2011 /PRNewswire/ -- Nearly 26 million American adults and children have diabetes today and by the year 2025, this condition is projected to affect 438 million worldwide, or 7.8% of the adult population.(1,2) One of the first lines of defense in disease management is dietary change, which highlights the significance of two recently published studies. Both suggest that including almonds in the diet may aid individuals with type 2 diabetes in maintaining cholesterol...
TAIPEI, Taiwan, Sept. 7, 2011 /PRNewswire-Asia/ -- TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. A combined 240 patients from 13 US sites plus 8 Taiwan sites have been enrolled to the trial. With six-month treatment and one-month follow-up, completion of the trial data analysis is expected in the early...
